Chemists have determined the precise structure of a promising anticancer compound approved with the U. S. Food and Substance Administration (FDA) pertaining to clinical trials throughout cancer patients. In the new study, scientists show which structure differs subtly from the version published by another group not too long ago, and that the previous structure associated with TIC10 in reality describes a molecule that will lacks TIC10's anticancer activity.
